Cordis Redux

article image

It wasn’t the biggest deal in medtech this year, but Ajax Health’s billion-dollar deal for the cardiovascular giant could be the most promising. Ajax is marshaling the power of venture capital and some of the leading private equity players as it pursues ambitious plans to return this once leader in cardiovascular devices to prominence.

Two decades-plus ago, Cordis Corp. was one of if not the big dog in cardiovascular devices, pioneers in bare-metal coronary stents, and a formidable presence in the cardiac cath lab. But as interventional cardiology matured, the segment became more challenging, demanding ever greater commitments in clinical trials and technology development even as many of the products in the portfolio became commodities in a cost-squeezed healthcare system. It didn’t help that Cordis lost its market leadership in stents just as drug-eluting stents emerged as a major product line. By the time Johnson & Johnson decided it no longer saw a return on its investment in interventional cardiology and sold the business to drug wholesale giant Cardinal Health in 2015 for what seemed a fraction of its value a decade earlier, few industry observers were surprised.


This article is restricted to subscribers only.

To continue reading, select one of the options below:

Existing Subscriber?

Sign In to continue reading.

Need Multi-User Access?

Gain access for your entire organization.

Get Quote Check to see if your company already has access

Subscribe to MedTech Strategist:

Actionable intelligence exploring the people, challenges, and opportunities impacting the global medtech community.

Subscribe to MedTech Strategist
Sign up for All-Access

Join our global community with a subscription to both MedTech Strategist and Market Pathways for one low price.



We're here to help! Please contact us at: